Lupus & antiphospholipid syndrome
Analysis of the Longitudinal Behavior of Serum Levels of Soluble Flt1 and Placental Growth Factor in Pregnant Patients With Systemic Lupus Erythematosus
Authors' conclusion
Pregnant patients with SLE who developed PE had higher sFlt1 levels and sFlt1:PlGF ratios and lower PlGF levels, and these last two changes were detected at the beginning of second trimester, before clinical manifestation. SLE activity did not interfere with longitudinal behavior of these angiogenic markers.
Study context
- Population
- Pregnant patients with systemic lupus erythematosus (SLE); serum samples at 14–18, 24–26, 30–32, 34–36 and 38–40 weeks527 samples
- Participants
- 163 patients
- Exposure
- Inactive SLE vs active SLE vs inactive SLE with preeclampsia
- Inactive SLEn = 109reference
- Active diseasen = 33
- Preeclampsia (PE)n = 21
- Outcome
- Longitudinal trajectories of serum sFlt1, PlGF and sFlt1:PlGF ratio
Methodological detailslongitudinal, linear models with random effects
- Longitudinal
- Linear models with random effects
Main finding
As reported in the abstract
Serum sFlt1, PlGF and sFlt1:PlGF ratio
- PE: higher mean soluble Flt1 (sFlt1) and sFlt1:Placenta growth factor (PlGF) ratios and lower PlGF than inactive and active SLE (exploratory analysis)
- P = 0.01 to P < 0.001
Observational data: associations, not effects.
Original publication
Analysis of the Longitudinal Behavior of Serum Levels of Soluble Flt1 and Placental Growth Factor in Pregnant Patients With Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). Published 2 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →